JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

Home・Aktien・Lisata Therapeutics

L
Lisata Therapeutics

Geschlossen

3.11 -2.81

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.99

Max

3.16

Schlüsselkennzahlen
By Trading Economics
Einkommen	1.3M -3M
Verkäufe	100K 100K
Gewinnspanne	-2,954
Angestellte	21

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-15M 24M
Vorheriger Eröffnungskurs	5.92
Vorheriger Schlusskurs	3.11

Lisata Therapeutics Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Apr. 2026, 23:15 UTC

Wichtige Nachrichtenereignisse

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27. Apr. 2026, 23:08 UTC

Ergebnisse

Wichtige Markttreiber

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27. Apr. 2026, 23:58 UTC

Ergebnisse

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27. Apr. 2026, 23:58 UTC

Ergebnisse

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27. Apr. 2026, 23:56 UTC

Ergebnisse

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27. Apr. 2026, 23:56 UTC

Ergebnisse

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27. Apr. 2026, 23:48 UTC

Market Talk

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27. Apr. 2026, 23:42 UTC

Market Talk

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27. Apr. 2026, 23:34 UTC

Market Talk

Wichtige Nachrichtenereignisse

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27. Apr. 2026, 23:30 UTC

Market Talk

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27. Apr. 2026, 23:08 UTC

Market Talk

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27. Apr. 2026, 23:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. Apr. 2026, 23:02 UTC

Market Talk

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27. Apr. 2026, 22:42 UTC

Market Talk

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27. Apr. 2026, 22:10 UTC

Ergebnisse

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27. Apr. 2026, 22:09 UTC

Ergebnisse

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27. Apr. 2026, 22:09 UTC

Ergebnisse

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27. Apr. 2026, 22:09 UTC

Ergebnisse

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27. Apr. 2026, 21:56 UTC

Ergebnisse

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27. Apr. 2026, 21:55 UTC

Ergebnisse

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27. Apr. 2026, 21:55 UTC

Ergebnisse

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27. Apr. 2026, 21:44 UTC

Ergebnisse

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27. Apr. 2026, 21:43 UTC

Ergebnisse

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27. Apr. 2026, 21:41 UTC

Ergebnisse

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27. Apr. 2026, 21:41 UTC

Ergebnisse

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27. Apr. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. Apr. 2026, 20:50 UTC

Market Talk

Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

27. Apr. 2026, 20:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

27. Apr. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27. Apr. 2026, 20:39 UTC

Ergebnisse

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Peer-Vergleich

Kursveränderung

Lisata Therapeutics Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lisata Therapeutics – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Gewinn vor Steuern

Verkäufe

Betriebsergebnis

Über Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.